A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)

NCT05347225 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematological Malignancies

Interventions

DRUG: Nemtabrutinib

Sponsor

Merck Sharp & Dohme LLC